Return to Cancer Alert Section
Data on cancer gene therapy discussed by researchers at University of Oxford
April 28th, 2008
2008 APR 28 -- "Adenovirus gene therapy for intraperitoneal (IP) cancer is limited in clinical trials by inefficient tumor cell transduction and development of peritoneal adhesions. We have shown previously that normal virus tropism can be ablated by physically shielding the virus surface with reactive hydrophilic polymers and that linkage of novel ligands enables virus '' retargeting '' through chosen receptors," scientists writing in the journal Molecular Therapy report. "To achieve tumor-selective infection, polymer-coated virus was retargeted using murine epidermal growth factor (mEGF). The resulting mEGF-polymer coated adenovirus lost its normal broad tropism and transduced cells selectively via the EGF receptor (EGFR). We assessed whether this approach could be used to target lytic '' virotherapy '' using wild-type adenovirus (Ad5WT) in a peritoneal xenograft model of human ovarian cancer. Oncolytic activity of Ad5WT was retained following polymer coating and mEGF-retargeting. Importantly, adhesion formation was markedly decreased compared with the unmodified virus, and no dose-limiting toxicities were observed following treatment with mEGF-retargeted polymer-coated virus," wrote J. Morrison and colleagues, University of Oxford. The researchers concluded: "Restricting virus tropism by physical coating, coupled with tumor-selective retargeting promises to combine good anticancer efficacy with acceptable toxicity, enabling application of elevated virus doses leading to an improved therapeutic outcome." Morrison and colleagues published their study in Molecular Therapy (Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Molecular Therapy, 2008;16(2):244-251). Additional information can be obtained by contacting J. Morrison, University of Oxford, John Radcliffe Hospital, Women's Center, Nuffield Dept. of Obstetrics & Gynecology, Oxford OX3 9DU, UK. The publisher of the journal Molecular Therapy can be contacted at: Nature Publishing Group, 75 Varick Street, 9TH Floor, New York, NY 10013-1917, USA. Keywords: United Kingdom, Oxford, Adenoviridae, Biotechnology, Cancer Gene Therapy, Clinical Trial Research, Drug Development, Genetics, Genomics, Gynecology, Molecular Research, Molecular Therapies, Oncology, Ovarian Cancer, Ovarian Carcinoma, Pharmaceuticals, Treatment, Virotherapy, Women's Health, University of Oxford. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2008, Biotech Business Week via NewsRx.com.
Return to Cancer Alert Section
|
